CN1309663A - 抗血管生成蛋白及其应用 - Google Patents

抗血管生成蛋白及其应用 Download PDF

Info

Publication number
CN1309663A
CN1309663A CN99808686A CN99808686A CN1309663A CN 1309663 A CN1309663 A CN 1309663A CN 99808686 A CN99808686 A CN 99808686A CN 99808686 A CN99808686 A CN 99808686A CN 1309663 A CN1309663 A CN 1309663A
Authority
CN
China
Prior art keywords
cell
protein
fragment
tumstatin
arresten
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99808686A
Other languages
English (en)
Chinese (zh)
Inventor
拉格赫阿姆·凯卢里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of CN1309663A publication Critical patent/CN1309663A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
CN99808686A 1998-06-17 1999-06-17 抗血管生成蛋白及其应用 Pending CN1309663A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8968998P 1998-06-17 1998-06-17
US60/089,689 1998-06-17
US12617599P 1999-03-25 1999-03-25
US60/126,175 1999-03-25

Publications (1)

Publication Number Publication Date
CN1309663A true CN1309663A (zh) 2001-08-22

Family

ID=26780845

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99808686A Pending CN1309663A (zh) 1998-06-17 1999-06-17 抗血管生成蛋白及其应用

Country Status (8)

Country Link
EP (1) EP1086129A1 (https=)
JP (3) JP2002517999A (https=)
KR (1) KR100682666B1 (https=)
CN (1) CN1309663A (https=)
AU (1) AU753249B2 (https=)
CA (1) CA2331332A1 (https=)
IL (1) IL140239A0 (https=)
WO (1) WO1999065940A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101962404A (zh) * 2010-06-17 2011-02-02 中国热带农业科学院热带生物技术研究所 一种用于治疗血管瘤的蛋白质
CN111087477A (zh) * 2020-01-03 2020-05-01 四川大学华西医院 GBM-7S(α1)-NC1(α3)融合蛋白及其制备方法
WO2023051848A1 (zh) * 2021-09-29 2023-04-06 陕西巨子生物技术有限公司 一种抗肿瘤重组胶原蛋白及其制备方法和应用
CN119286901A (zh) * 2024-11-21 2025-01-10 西安巨子生物基因技术股份有限公司 一种重组iv型胶原蛋白及其制备方法和应用
CN120554490A (zh) * 2025-05-28 2025-08-29 广西福莱明生物制药有限公司 一种重组iv型人源化胶原蛋白及其纯化工艺

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP1337633A2 (en) * 2000-01-07 2003-08-27 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
CA2368681A1 (en) * 2000-02-10 2001-08-16 Zymogenetics, Inc. Anti-angiogenic intestinal peptides, zdint5
EP1363938B1 (en) 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
CN1455682A (zh) 2001-01-05 2003-11-12 百疗医株式会社 包括编码抗－血管生成蛋白或者其部分的基因的用于类风湿性关节炎的基因治疗的组合物
EP1389997B1 (en) * 2001-04-13 2010-12-08 Boyce Thompson Institute For Plant Research Methods and compositions for stable transgenic plant pharmaceuticals and their use as contraceptives
CN100447155C (zh) * 2001-05-23 2008-12-31 中国科学院上海上海生命科学研究院 具有抑制内皮细胞生长活性的重组人内皮生长抑制蛋白
AU2002329643B2 (en) * 2001-07-27 2006-11-16 University Of Kansas Medical Center Crystallized structure of type IV collagen NC1 domain hexamer
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
JP4843767B2 (ja) * 2005-08-31 2011-12-21 国立大学法人 岡山大学 がん細胞特異的遺伝子発現法を用いた血管新生阻害薬
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
DK2744831T3 (en) * 2011-08-17 2018-03-05 Univ Colorado Regents TRANSFERRIN-TUMSTATIN-FUSION PROTEIN AND PROCEDURES FOR PREPARING AND USING THE SAME
WO2014180288A1 (zh) * 2013-05-06 2014-11-13 中国药科大学 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876332A (en) * 1987-10-08 1989-10-24 Regents Of The Univeristy Of Minnesota Polypeptides with type IV collagen activity
US5114840A (en) * 1989-07-07 1992-05-19 Karl Tryggvason Method for determining the nucleotide sequence of a novel α5(IV) chain of human type IV collagen
US5354690A (en) * 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5082926A (en) * 1989-12-14 1992-01-21 Regents Of The University Of Minnesota Polypeptide with type iv collagen cell adhesion, spreading and motility activity
US5081031A (en) * 1989-12-14 1992-01-14 Regents Of The University Of Minnesota Synthetic polypeptide with type iv collagen activity
US5424408A (en) * 1990-11-30 1995-06-13 Yale University α-3 chain type IV collagen polynucleotides
US5731192A (en) * 1993-08-27 1998-03-24 Yale University Collagen COL4A6: gene, protein and method of detecting collagen deficiency
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101962404A (zh) * 2010-06-17 2011-02-02 中国热带农业科学院热带生物技术研究所 一种用于治疗血管瘤的蛋白质
CN111087477A (zh) * 2020-01-03 2020-05-01 四川大学华西医院 GBM-7S(α1)-NC1(α3)融合蛋白及其制备方法
CN111087477B (zh) * 2020-01-03 2021-10-08 四川大学华西医院 GBM-7S(α1)-NC1(α3)融合蛋白及其制备方法
WO2023051848A1 (zh) * 2021-09-29 2023-04-06 陕西巨子生物技术有限公司 一种抗肿瘤重组胶原蛋白及其制备方法和应用
CN119286901A (zh) * 2024-11-21 2025-01-10 西安巨子生物基因技术股份有限公司 一种重组iv型胶原蛋白及其制备方法和应用
CN119286901B (zh) * 2024-11-21 2025-09-09 西安巨子生物基因技术股份有限公司 一种重组iv型胶原蛋白及其制备方法和应用
CN120554490A (zh) * 2025-05-28 2025-08-29 广西福莱明生物制药有限公司 一种重组iv型人源化胶原蛋白及其纯化工艺
CN120554490B (zh) * 2025-05-28 2025-10-31 广西福莱明生物制药有限公司 一种重组iv型人源化胶原蛋白及其纯化工艺

Also Published As

Publication number Publication date
CA2331332A1 (en) 1999-12-23
JP2008301823A (ja) 2008-12-18
EP1086129A1 (en) 2001-03-28
AU753249B2 (en) 2002-10-10
IL140239A0 (en) 2002-02-10
KR100682666B1 (ko) 2007-02-15
AU4575599A (en) 2000-01-05
WO1999065940A1 (en) 1999-12-23
JP2002517999A (ja) 2002-06-25
KR20010053018A (ko) 2001-06-25
JP2008019271A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
CN1309663A (zh) 抗血管生成蛋白及其应用
US8618264B2 (en) Anti-CD147 antibodies, methods and uses
CN1225129A (zh) 嵌合异源多亚基粘附素
JP2006508015A (ja) 抗血管形成性タンパク質およびフラグメントおよびその使用方法
CN1284130A (zh) 内抑制素的突变体,具有抗血管生成活性的“em1”及其使用方法
CN1191860C (zh) 利用整联蛋白α4亚单位的拮抗剂治疗纤维变性的方法
UA127450C2 (uk) Рекомбінантний поліпептид, що зв'язується з cd123
JPH07504812A (ja) 細胞付着を促進するための新規なポリペプチド
CN101119745B (zh) 凝集素组合物和调节对抗原免疫应答的方法
CN1236390A (zh) 血管形成因子及其在治疗心血管疾病中的用途
UA129672C2 (uk) Антитіло до trem-1 та його застосування
CN1491624A (zh) 经修饰的生物材料
CN1900116A (zh) 抗－LT－β－R抗体、含有该抗体的药用组合物及其制药应用
CN1420926A (zh) 抗生血管蛋白和片段及其应用方法
JP2008280266A (ja) モノクローナル抗体
JPH09511387A (ja) 新規な細胞表面受容体、抗体組成物、及びこれらの使用方法
JP3623230B2 (ja) キメラ受容体ポリペプチド，ヒトｈ１３タンパク質，ならびにその使用
US6759047B1 (en) Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) Anti-angiogenic proteins and fragments and methods of use thereof
US20090028847A1 (en) Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof
AU2003213064C1 (en) Methods of therapy and diagnosis
EP1268798A2 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
CN1326359A (zh) 人绒膜促性腺激素疫苗
US20080167232A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other indogen domains
MacDonald Zebrafish to humans: evolution of the 3-chain of type IV collagen and emergence of the autoimmune epitopes associated with Goodpasture syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20010822